Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Astrazeneca (AZNCF) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to $2.3 billion.

  • Astrazeneca's Profit After Tax rose 5526.67% to $2.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $10.2 billion, marking a year-over-year increase of 4533.45%. This contributed to the annual value of $10.2 billion for FY2025, which is 4533.45% up from last year.
  • Astrazeneca's Profit After Tax amounted to $2.3 billion in Q4 2025, which was up 5526.67% from $2.5 billion recorded in Q3 2025.
  • Astrazeneca's Profit After Tax's 5-year high stood at $2.9 billion during Q1 2025, with a 5-year trough of -$1.7 billion in Q3 2021.
  • For the 5-year period, Astrazeneca's Profit After Tax averaged around $1.3 billion, with its median value being $1.5 billion (2021).
  • As far as peak fluctuations go, Astrazeneca's Profit After Tax plummeted by 35360.98% in 2021, and later surged by 40555.56% in 2023.
  • Quarter analysis of 5 years shows Astrazeneca's Profit After Tax stood at -$346.0 million in 2021, then surged by 360.69% to $902.0 million in 2022, then rose by 6.32% to $959.0 million in 2023, then skyrocketed by 56.41% to $1.5 billion in 2024, then skyrocketed by 55.27% to $2.3 billion in 2025.
  • Its Profit After Tax was $2.3 billion in Q4 2025, compared to $2.5 billion in Q3 2025 and $2.4 billion in Q2 2025.